Literature DB >> 8300219

Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

M P Jiménez de Bagüés1, P H Elzer, J M Blasco, C M Marín, C Gamazo, A J Winter.   

Abstract

Experiments were performed with BALB/c mice to elucidate the roles of humoral and cell-mediated immune responses in the acquisition of protective immunity to Brucella ovis and to compare infection immunity with immunity developed through vaccination with a hot saline extract (HS) of B. ovis. Mice convalescing from a primary infection with B. ovis displayed a high level of resistance to reinfection, as evidenced by splenic bacterial counts decreased over 10,000-fold from control groups at 2 weeks after challenge. Passive transfer assays revealed that protection was mediated by both T lymphocytes and antibodies but that antibodies had a substantially greater role on the basis of log units of protection that were transferred. Antibodies specific for HS proteins in sera from convalescent mice were predominantly of the immunoglobulin G 2a and 3 isotypes. Vaccination with HS conferred good protection against B. ovis, but protection was greatly enhanced by the incorporation of QS-21 or other adjuvants. Protection provided by the HS vaccine resulted largely from immune responses to its protein moieties. A critical evaluation of the protective efficacy of the rough lipopolysaccharide component of HS was precluded by its poor immunogenicity in BALB/c mice. HS-QS-21 afforded protection against challenge infection with B. ovis as good as that which developed after a primary infection and as good as or better than that provided by attenuated Brucella melitensis vaccine strain Rev 1. Passive transfer experiments confirmed that the magnitudes of both humoral and cell-mediated forms of protective immunity were equivalent in mice vaccinated with HS-QS-21 and those recovering from a primary infection. Protective immunity to B. ovis in mice therefore resembled that to Brucella abortus, except that the relative roles of humoral and cell-mediated immunity, rather than being equivalent, were shifted toward a greater role for antibodies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8300219      PMCID: PMC186150          DOI: 10.1128/iai.62.2.632-638.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  The persistence of antibodies against Brucella ovis and Brucella abortus in rams following vaccination: a field study.

Authors:  D R Ris
Journal:  N Z Vet J       Date:  1967-06       Impact factor: 1.628

2.  Brucella melitensis Rev-1 vaccine as a cause of human brucellosis.

Authors:  J M Blasco; R Díaz
Journal:  Lancet       Date:  1993-09-25       Impact factor: 79.321

3.  Survival of virulent and attenuated strains of Brucella abortus in normal and gamma interferon-activated murine peritoneal macrophages.

Authors:  S M Jones; A J Winter
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Early gamma interferon production by natural killer cells is important in defense against murine listeriosis.

Authors:  P L Dunn; R J North
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

Review 5.  Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection.

Authors:  A Sher; R T Gazzinelli; I P Oswald; M Clerici; M Kullberg; E J Pearce; J A Berzofsky; T R Mosmann; S L James; H C Morse
Journal:  Immunol Rev       Date:  1992-06       Impact factor: 12.988

6.  Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams.

Authors:  J M Blasco; C Gamazo; A J Winter; M P Jiménez de Bagüés; C Marín; M Barberán; I Moriyón; B Alonso-Urmeneta; R Díaz
Journal:  Vet Immunol Immunopathol       Date:  1993-08       Impact factor: 2.046

7.  Listeria monocytogenes infection in beta 2 microglobulin-deficient mice.

Authors:  A D Roberts; D J Ordway; I M Orme
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

8.  Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses.

Authors:  M J Newman; J Y Wu; B H Gardner; K J Munroe; D Leombruno; J Recchia; C R Kensil; R T Coughlin
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

9.  Evaluation of vaccines and of antigen therapy in a mouse model for Brucella ovis.

Authors:  M P Jiménez de Bagüés; C M Marín; M Barberán; J M Blasco
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

10.  A protective role of gamma/delta T cells in primary infection with Listeria monocytogenes in mice.

Authors:  K Hiromatsu; Y Yoshikai; G Matsuzaki; S Ohga; K Muramori; K Matsumoto; J A Bluestone; K Nomoto
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

View more
  24 in total

1.  Effect of early antibiotic treatment on the antibody response to cytoplasmic proteins of Brucella melitensis in mice.

Authors:  R A Bowden; G C Racaro; P C Baldi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis.

Authors:  L E Lindler; T L Hadfield; B D Tall; N J Snellings; F A Rubin; L L Van De Verg; D Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  Regulation of the mitogen-activated protein kinases by Brucella spp. expressing a smooth and rough phenotype: relationship to pathogen invasiveness.

Authors:  María P Jiménez de Bagüés; Antoine Gross; Annie Terraza; Jacques Dornand
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

4.  Stability of poly(epsilon-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis.

Authors:  Maite Estevan; Carlos Gamazo; Fernando Martínez-Galan; Juan M Irache
Journal:  AAPS PharmSciTech       Date:  2008-10-16       Impact factor: 3.246

5.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

6.  Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Authors:  S Sasaki; K Sumino; K Hamajima; J Fukushima; N Ishii; S Kawamoto; H Mohri; C R Kensil; K Okuda
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  Analysis of the behavior of eryC mutants of Brucella suis attenuated in macrophages.

Authors:  Sonja Burkhardt; Maria P Jiménez de Bagüés; Jean-Pierre Liautard; Stephan Köhler
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

8.  A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Silvia de la Barrera; Silvia M Estein; Laura Bruno; Raúl Bowden; Karina A Pasquevich; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

9.  Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.

Authors:  Karina A Pasquevich; Silvia M Estein; Clara García Samartino; Clara García Samartino; Astrid Zwerdling; Lorena M Coria; Paula Barrionuevo; Carlos A Fossati; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

10.  Surface exposure of outer membrane protein and lipopolysaccharide epitopes in Brucella species studied by enzyme-linked immunosorbent assay and flow cytometry.

Authors:  R A Bowden; A Cloeckaert; M S Zygmunt; S Bernard; G Dubray
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.